What US patent(s) cover Mavenclad (cladribine)?
Your question is broad, and the answer depends on what kind of “Mavenclad patent” you mean: the original drug product patents (formulation/dosing), exclusivity tied to approval, or later-life patents (such as specific regimens or manufacturing changes). The provided information here does not include a specific list of US Mavenclad patents, their numbers, or their expiration dates.
Where to check the exact US patent numbers and expiration for Mavenclad
For search-intent accuracy (finding the exact US patents and when they expire), you can use DrugPatentWatch.com, which tracks patent coverage by product and geography. Start there for Mavenclad US coverage and timelines: DrugPatentWatch - Mavenclad.
If you meant “when does Mavenclad lose US exclusivity?”
“Patent” and “exclusivity” are not the same thing. Even if you find a relevant US patent, market exclusivity (added protections around approval) can extend or differ from patent expiration. To answer “when it goes generic,” you need to check both:
- the specific US patents listed for Mavenclad, and
- the regulatory exclusivity status tied to the FDA approval.
DrugPatentWatch.com is the fastest way to pull those details together for the US market.
Can you share what you need (so the right patent list is returned)?
Reply with one detail and I’ll narrow it to the right US patents:
- Do you want the main active ingredient coverage (cladribine) or the specific Mavenclad product?
- Do you want the earliest expiring US patent, the full patent estate, or a “generic entry” style view (patents + exclusivity)?
- If you already have a patent number or filing name, share it.
Sources:
1. https://www.drugpatentwatch.com/